logo
Plus   Neg
Share
Email

Regeneron Enters Manufacturing And Supply Deal With BARDA For REGN-COV2

Regeneron Pharmaceuticals, Inc. (REGN) announced it has been awarded a $450 million manufacturing and supply contract to manufacture and supply REGN-COV2 for BARDA and U.S. Department of Defense. The company said the deal supports continued manufacturing so that the product could be made available immediately in the United States if clinical trials are successful and the FDA grants Emergency Use Authorization.

REGN-COV2 is Regeneron's investigational double antibody cocktail that is currently in two Phase 2/3 clinical trials for the treatment of COVID-19 and in a Phase 3 trial for the prevention of COVID-19 infection.

Shares of Regeneron Pharma were up 3% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL. U.S. President Donald Trump has issued executive orders to ban Chinese mobile application TikTok as well as WeChat, citing a threat to national security and its economy. China's ByteDance Ltd. owns TikTok, a video-sharing mobile app, while Tencent Holdings Ltd. owns WeChat, a messaging, social media, and electronic payment app.
Follow RTT